Skip to main content
KNSAKiniksa Pharmaceuticals InternaBuy Wait6.2·$62.84-0.33%
KNSA · Why this verdict

Why Kiniksa Pharmaceuticals Interna (KNSA) is rated BUY WAIT

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictBUY WAIT
Overall score6.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

The company is delivering exceptional 56% year-over-year revenue growth with outstanding cash conversion, but single-product and single-supplier concentration creates a binary risk that the current price leaves little margin for error—and the unfavorable reward/risk geometry with only 5.5% headroom to the take-profit level limits the case for adding exposure.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

Despite strong revenue growth, the company missed earnings estimates in three of the last four quarters with an average shortfall of roughly 9.3%, suggesting that cost management or margin conversion has been unpredictable.

Stable
Earnings
Expectation
EPS surprise should turn consistently positive—exceeding 5% for two consecutive quarters—if the earnings delivery track record is improving.

CounterThe most recent quarter posted a 69% positive surprise, meaningfully reversing the prior trend; one strong beat after three misses could signal a reset in guidance discipline rather than continued volatility in earnings delivery.

Revenue is growing at 56% year-over-year, a pace that leads the peer group, and a PEG ratio of 0.20 suggests the market has not yet fully priced this trajectory into the valuation.

Stable
Growth
Expectation
Revenue growth should sustain above 30% year-over-year for at least two consecutive quarters if the growth story remains intact.

CounterThree of the last four quarters missed earnings estimates, with an average shortfall of roughly 9.3%; if top-line growth is not translating into earnings power, the high revenue rate may be masking underlying profitability challenges that will eventually compress the multiple.

Free cash flow is running at 161% of net income, indicating the business is generating far more cash than accounting earnings suggest and supporting financial flexibility for reinvestment or balance sheet management.

Stable
Quality
Expectation
The FCF-to-net-income ratio should remain above 100% for two consecutive reporting periods if the cash quality thesis holds.

CounterStrong cash conversion can mask the underlying product and supplier concentration risks; a single adverse event at the key product level could abruptly interrupt cash flows irrespective of the current conversion quality.

The business carries high concentration risk at both the product and supplier level—a single product accounts for the majority of revenue and a single external partner is the sole supplier—creating binary downside in any disruption scenario.

Improving
Bear case
Expectation
Concentration risk would ease if the company adds a second meaningful revenue source, reducing reliance on the primary product below 50% of total revenue over the next two annual reporting periods.

CounterSingle-product businesses with strong market penetration can generate more durable cash flows than diversified ones in their early growth phases; concentration may reflect focus and execution discipline rather than structural fragility.

Per-dimension breakdown

Value

4.4/10data confidence 100%
ComponentSub-score
P/E1.6
P/S5.9
EV/EBITDA0.0
Fwd P/E2.9
PEG10.0
Analyst target4.0
  • Forward P/E: 37.0x
  • PEG: 0.25

Quality

7.2/10data confidence 100%
ComponentSub-score
ROE4.6
ROA5.5
Gross margin6.9
Op margin5.5
Net margin4.8
Current ratio9.2
FCF quality10.0
Moat8.4
Piotroski F10.0
  • Excellent cash conversion: 161% FCF/NI
  • Wide economic moat
  • Compounder quality: strong returns + growth
  • Strong Piotroski F-Score: 9/9

Growth

10.0/10data confidence 67%
ComponentSub-score
Rev growth10.0
EPS growth10.0
  • Strong growth: 56% YoY

Momentum

2.7/10data confidence 100%
ComponentSub-score
RSI5.5
MACD0.0
OBV1.2
MA position6.0
Volume0.9
  • Volume distribution (falling OBV)
  • Above 200-day MA

Sentiment

7.6/10data confidence 100%
ComponentSub-score
LLM sentiment8.5
Analyst rating7.9
Price target6.2
  • LLM news sentiment: +0.70 (n=1)
  • Light analyst coverage (8.0) — signal dampened

Insider

5.2/10data confidence 100%
ComponentSub-score
materiality2.0
insider conviction2.0
holder change10.0
notable moves7.0
  • Heavy insider selling — $32,832,792 (0.677% of mkt cap)
  • Institutions accumulating

Peer rank

6.5/10data confidence 80%
ComponentSub-score
value rank1.3
quality rank6.6
growth rank9.1
  • Industry growth leader
  • Conservative debt levels

Technical

6.1/10data confidence 100%
ComponentSub-score
bollinger5.3
support resistance4.3
52w position8.6

Risk (lower is worse)

6.6/10data confidence 100%
ComponentSub-score
short interest4.5
days to cover6.3
volatility2.1
put call10.0
implied vol3.3
beta10.0
debt equity9.9
  • High IV: 60%
  • Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

3.0/10data confidence 100%
ComponentSub-score
erm5.0
earnings history0.0
earnings timing5.0
surprise avg0.0
news activity5.0
  • Earnings concerns: 1B/3M
  • Earnings in 3 days

How the verdict was assembled

Engine trigger

Earnings in 3 days. Wait until post-earnings.

Engine technical detail
verdict_path: L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BAND
Passed (3)
  • NEWS_BOOST:ANALYST:0.70
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (4)
  • MOMENTUM:2.7<4.5
  • ASYMMETRY:-0.6=NEGATIVE
  • INSIDER:0.68%=HEAVY
  • EARNINGS_PROXIMITY:3d<=7d
Warning (1)
  • 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.57
Upside
-5.7%
Downside
10.0%
Sizing output
STARTER

SetupRange Bound RSI 50 mid-range, Bollinger mid-band

EdgeNo clear edge No clear edge identified

SuitabilityAggressive MCap $4.9B<$5B

Investment implication

A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings in 3 days. Wait until post-earnings. The 10-dimension scores remain Growth at 10.0 (strongest), but MOMENTUM:2.7<4.5 also fails — the news block is the proximate trigger, not the sole driver.

The strongest dimensions are Growth at 10.0, Sentiment at 7.6, and Quality at 7.2; the weakest are Momentum at 2.7, Catalyst at 3.0, and Value at 4.4. The V9 engine flagged 4 failed gates with 1 warning, producing an asymmetric reward-to-risk of -0.57 and an engine sizing output of STARTER.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Industry Leading Revenue Growth

    Trip ifRevenue growth falls below 20% YoY for 2 consecutive quarters.

  • P2Exceptional Cash Conversion Quality

    Trip ifFCF-to-net-income ratio falls below 80% for 2 consecutive reporting periods.

  • P3Single Product Supplier Concentration

    Trip ifPrimary product revenue share falls below 50% of total revenue for 2 consecutive annual reporting periods.

  • P4Inconsistent Earnings Delivery

    Trip ifEPS surprise rises above 10% for 2 consecutive quarters.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home Stocks KNSA Why this verdict